June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Changes in choroidal vasculature predict visual outcomes in Stargardt disease
Author Affiliations & Notes
  • Alexander Ho
    Doheny Image Reading Center, Doheny Eye Institute, Los Angeles, California, United States
  • Siva Balasubramanian
    Doheny Image Reading Center, Doheny Eye Institute, Los Angeles, California, United States
    Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
  • Anamika Jha
    Doheny Image Reading Center, Doheny Eye Institute, Los Angeles, California, United States
  • Beatriz Munoz
    Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
  • Rupert Wolfgang Strauss
    Moorfields Eye Hospital, London, United Kingdom
    Department of Ophthalmology, Johannes Kepler University, Linz, Austria
  • Michael S Ip
    Doheny Image Reading Center, Doheny Eye Institute, Los Angeles, California, United States
    Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
  • Srinivas R Sadda
    Doheny Image Reading Center, Doheny Eye Institute, Los Angeles, California, United States
    Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
  • Hendrik P Scholl
    Department of Ophthalmology, University of Basel, Basel, Switzerland
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Alexander Ho, None; Siva Balasubramanian, None; Anamika Jha, None; Beatriz Munoz, None; Rupert Strauss, None; Michael Ip, Boehringer Ingelheim (C), Genentech (C), Omeros (C), ThromboGenics (C); Srinivas Sadda, Allergan (C), Carl Zeiss Meditec (F), CenterVue (C), Genentech (C), Iconic Therapeutics (C), Optos (C), Optos (F), ThromboGenics (C), Topcon (R); Hendrik Scholl, Acucela Inc. (F), Boehringer Ingelheim Pharma GmbH & Co. KG (C), Daiichi Sankyo (C), Genentech Inc./F. Hoffmann-La Roche Ltd. (R), Gensight Biologics (C), Genzyme Corp./Sanofi (R), Gerson Lehrman Group (C), Guidepoint (C), Intellia Therapeutics (C), NightstaRx Ltd. (F), QLT, Inc. (F), ReNeuron Group Plc/Ora Inc. (R), Shire (C), Vision Medicines, Inc. (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4637. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Alexander Ho, Siva Balasubramanian, Anamika Jha, Beatriz Munoz, Rupert Wolfgang Strauss, Michael S Ip, Srinivas R Sadda, Hendrik P Scholl; Changes in choroidal vasculature predict visual outcomes in Stargardt disease. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4637.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Vascular status of the choroid in ABCA4-related Stargardt disease (STGD1) remains unclear. We hypothesized that alterations in choroidal vasculature contribute to changes in visual acuity. In this analysis, we evaluated the morphofunctional relationship between choroid and visual acuity in a Stargardt disease cohort.

Methods : Enhanced depth imaging (EDI) optical coherence tomography (OCT) scans and best-corrected visual acuity (BCVA) were collected at baseline, six, and 12 month follow-up visits from 37 eyes of 37 subjects from the prospective multicenter “Natural History of Progression of Stargardt Disease” (ProgStar) study. Various choroidal parameters at the sub-fovea including choroidal area (CA), luminal area (LA) and choroidal vascularity index (CVI: proportion of LA to CA) were computed using a previously reported image binarization technique (Figure 1). Repeated measures ANOVA was used to study the changes in vision and choroid during subsequent visits. The correlation between choroidal parameters and BCVA was assessed using Pearson and multiple linear regression analysis.

Results : Results are expressed as mean ± standard deviation. The mean age of study subjects was 33 ± 14 years (range: 11-67), and 17 were female. BCVA was 0.82 ± 0.32 logMAR with spherical equivalent (SE) of refractive error of -3.02 ± 2.69 diopters. The mean CA, LA and CVI were 0.76 ± 0.21 mm2 (range: 0.34-1.26), 0.49 ± 0.14 mm2 (range: 0.22-0.80) and 0.64 ± 0.03 (0.56-0.70), respectively. CVI was negatively correlated (r = -0.44, p = 0.01) with logMAR equivalent BCVA, and positively correlated with LA (r = 0.34, p = 0.04), indicating worse visual acuity was associated with reduced choroidal vasculature. Age (r = -0.15, p = 0.38), SE (r = -0.07, p = 0.69) and CA (r = 0.21, p = 0.22) did not show a significant correlation with CVI. Multiple linear regression analysis also demonstrated CVI as a significant (p = 0.01) predictor of BCVA. The choroidal parameters and BCVA did not significantly change between follow-up visits.

Conclusions : The vascular component of the choroid appears to be related to visual function in Stargardt disease. Further replicative studies are required to confirm this relationship and better define the pathophysiologic mechanisms.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

Figure 1. EDI-OCT B-scan from a Stargardt patient’s eye. (A) Raw OCT B-scan. (B) OCT B-scan image following binarization; CA (within red) and LA (dark pixels within CA).

Figure 1. EDI-OCT B-scan from a Stargardt patient’s eye. (A) Raw OCT B-scan. (B) OCT B-scan image following binarization; CA (within red) and LA (dark pixels within CA).

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×